These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 15206117)

  • 1. Iron chelators and their therapeutic potential.
    Crichton RR; Ward RJ
    Met Ions Biol Syst; 2004; 41():185-219. PubMed ID: 15206117
    [No Abstract]   [Full Text] [Related]  

  • 2. Design of therapeutic chelating agents.
    Hider RC
    Biochem Soc Trans; 2002 Aug; 30(4):751-4. PubMed ID: 12196186
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The potential application of iron chelators for the treatment of neurodegenerative diseases.
    Hider RC; Roy S; Ma YM; Le Kong X; Preston J
    Metallomics; 2011 Mar; 3(3):239-49. PubMed ID: 21344071
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design, synthesis, and evaluation of novel bifunctional iron-chelators as potential agents for neuroprotection in Alzheimer's, Parkinson's, and other neurodegenerative diseases.
    Zheng H; Weiner LM; Bar-Am O; Epsztejn S; Cabantchik ZI; Warshawsky A; Youdim MB; Fridkin M
    Bioorg Med Chem; 2005 Feb; 13(3):773-83. PubMed ID: 15653345
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Thiosemicarbazones from the old to new: iron chelators that are more than just ribonucleotide reductase inhibitors.
    Yu Y; Kalinowski DS; Kovacevic Z; Siafakas AR; Jansson PJ; Stefani C; Lovejoy DB; Sharpe PC; Bernhardt PV; Richardson DR
    J Med Chem; 2009 Sep; 52(17):5271-94. PubMed ID: 19601577
    [No Abstract]   [Full Text] [Related]  

  • 6. Cell permeable iron chelators as potential cancer chemotherapeutic agents.
    Pahl PM; Horwitz LD
    Cancer Invest; 2005; 23(8):683-91. PubMed ID: 16377587
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The evolution of iron chelators for the treatment of iron overload disease and cancer.
    Kalinowski DS; Richardson DR
    Pharmacol Rev; 2005 Dec; 57(4):547-83. PubMed ID: 16382108
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic potential of iron chelators in diseases associated with iron mismanagement.
    Weinberg ED
    J Pharm Pharmacol; 2006 May; 58(5):575-84. PubMed ID: 16640825
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel chelators for cancer treatment: where are we now?
    Merlot AM; Kalinowski DS; Richardson DR
    Antioxid Redox Signal; 2013 Mar; 18(8):973-1006. PubMed ID: 22424293
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel chelators for central nervous system disorders that involve alterations in the metabolism of iron and other metal ions.
    Richardson DR
    Ann N Y Acad Sci; 2004 Mar; 1012():326-41. PubMed ID: 15105276
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis and biological evaluation of lipophilic iron chelators as protective agents from oxidative stress.
    Yavin E; Kikkiri R; Gil S; Arad-Yellin R; Yavin E; Shanzer A
    Org Biomol Chem; 2005 Aug; 3(15):2685-7. PubMed ID: 16032345
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Iron binding dendrimers: a novel approach for the treatment of haemochromatosis.
    Zhou T; Neubert H; Liu DY; Liu ZD; Ma YM; Kong XL; Luo W; Mark S; Hider RC
    J Med Chem; 2006 Jul; 49(14):4171-82. PubMed ID: 16821777
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Comparative evaluation of two models of hemosiderosis for analysis of iron chelators].
    Minina LT; Prostakova TM; Meshchano AIu; Kol'tsova GN; Bovenko VN
    Biull Eksp Biol Med; 1996 Sep; 122(9):359-60. PubMed ID: 8974501
    [No Abstract]   [Full Text] [Related]  

  • 14. Therapeutic application of iron chelators--present state and research trends.
    Peter HH
    J Pharmacol; 1985; 16(4):365-71. PubMed ID: 4094434
    [No Abstract]   [Full Text] [Related]  

  • 15. Metal ion chelating peptides with superoxide dismutase activity.
    Fisher AE; Naughton DP
    Biomed Pharmacother; 2005 May; 59(4):158-62. PubMed ID: 15862709
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Iron chelators can protect against oxidative stress through ferryl heme reduction.
    Reeder BJ; Hider RC; Wilson MT
    Free Radic Biol Med; 2008 Feb; 44(3):264-73. PubMed ID: 18215735
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Protection against hydrogen peroxide-mediated cytotoxicity in Friedreich's ataxia fibroblasts using novel iron chelators of the 2-pyridylcarboxaldehyde isonicotinoyl hydrazone class.
    Lim CK; Kalinowski DS; Richardson DR
    Mol Pharmacol; 2008 Jul; 74(1):225-35. PubMed ID: 18424550
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Iron: a new target for pharmacological intervention in neurodegenerative diseases.
    Whitnall M; Richardson DR
    Semin Pediatr Neurol; 2006 Sep; 13(3):186-97. PubMed ID: 17101458
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structure-activity relationships of novel iron chelators for the treatment of iron overload disease: the methyl pyrazinylketone isonicotinoyl hydrazone series.
    Kalinowski DS; Sharpe PC; Bernhardt PV; Richardson DR
    J Med Chem; 2008 Jan; 51(2):331-44. PubMed ID: 18159922
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Novel iron-chelating derivative of the neuroprotective peptide NAPVSIPQ shows superior antioxidant and antineurodegenerative capabilities.
    Blat D; Weiner L; Youdim MB; Fridkin M
    J Med Chem; 2008 Jan; 51(1):126-34. PubMed ID: 18078312
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.